Co-invest With Global Biotech and Pharmaceutical Leaders
Kineta is a clinical stage biotech company with a focus on immunotherapy to strengthen a patient’s innate immunity that has established strategic partnerships with industry leaders including Pfizer and Genentech.
Date & Time:
August 13, 12:00 PM EDT
Webinar: Details provided upon RSVP approval
About the Event:
Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. They have leveraged their expertise in innate immunity and immunology to advance a focused pipeline of investigational drugs to treat cancer, chronic pain, and virus infection. The Kineta scientific team has >10-year track record in innate immunity and cancer biology research and our core focus is exploiting novel drug targets in immuno-oncology.
- Kineta has established a pipeline of novel immunotherapies to treat diseases that have a particularly high unmet need.
- In April of 2018 Kineta formed a strategic partnership with Genentech that is accelerating the development of a novel, non-opioid chronic pain program.
- Kineta’s drug development programs are focused on therapeutic areas with multi-billion-dollar market potential. The immuno-oncology market currently totals $88B and is projected to grow to $158B in 2024. The neuropathic pain market currently totals $6.3B and is projected to grow to $9.9B in 2027.
Please join our webinar to hear from Kineta president Craig Philips about this exciting time for the company and the opportunities that lie ahead.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.